CR20150360A - Sistema de liberación transdérmica - Google Patents

Sistema de liberación transdérmica

Info

Publication number
CR20150360A
CR20150360A CR20150360A CR20150360A CR20150360A CR 20150360 A CR20150360 A CR 20150360A CR 20150360 A CR20150360 A CR 20150360A CR 20150360 A CR20150360 A CR 20150360A CR 20150360 A CR20150360 A CR 20150360A
Authority
CR
Costa Rica
Prior art keywords
release system
transdermal release
transdermal
patient
therapeutic system
Prior art date
Application number
CR20150360A
Other languages
English (en)
Inventor
Gabriel Wauer
Thomas Hille
Kevin John Smith
Helen Elizabeth Johnson
Gillian Elizabeth Mundin
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49816915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150360(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of CR20150360A publication Critical patent/CR20150360A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se relaciona con un método de tratamiento del dolor en un paciente al aplicar un sistema terapéutico transdérmico para la administración transdérmica de buprenorfina por 7 días sobre la piel de un paciente, dicho sistema terapéutico transdérmico comprendiendo una estructura de capa autoadhesiva conteniendo buprenorfina.
CR20150360A 2012-12-12 2015-07-09 Sistema de liberación transdérmica CR20150360A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736342P 2012-12-12 2012-12-12
PCT/EP2013/076325 WO2014090921A1 (en) 2012-12-12 2013-12-12 Transdermal delivery system

Publications (1)

Publication Number Publication Date
CR20150360A true CR20150360A (es) 2015-08-21

Family

ID=49816915

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150360A CR20150360A (es) 2012-12-12 2015-07-09 Sistema de liberación transdérmica

Country Status (26)

Country Link
US (3) US20150306093A1 (es)
EP (1) EP2931263A1 (es)
JP (1) JP2016502989A (es)
KR (1) KR20150096460A (es)
CN (1) CN105007906A (es)
AP (1) AP2015008525A0 (es)
AR (1) AR093940A1 (es)
AU (1) AU2013205080B2 (es)
BR (1) BR112015013660A2 (es)
CA (1) CA2894960A1 (es)
CL (1) CL2015001577A1 (es)
CR (1) CR20150360A (es)
DE (1) DE112013005945T5 (es)
EA (1) EA201591124A1 (es)
GB (1) GB2523715A (es)
HK (1) HK1215677A1 (es)
IL (1) IL239223A0 (es)
MX (1) MX2015007348A (es)
NZ (1) NZ628092A (es)
PE (1) PE20151147A1 (es)
PH (1) PH12015501169A1 (es)
SG (1) SG11201504286VA (es)
TN (1) TN2015000201A1 (es)
TW (1) TW201438765A (es)
WO (1) WO2014090921A1 (es)
ZA (1) ZA201504964B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
TW201338813A (zh) 2011-12-12 2013-10-01 洛曼治療系統股份有限公司 經皮遞送系統
WO2014195352A1 (en) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
CN107660207B (zh) 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
EP3349737A4 (en) * 2015-09-14 2019-05-15 Amneal Pharmaceuticals LLC SYSTEM FOR TRANSDERING
KR101695603B1 (ko) * 2016-11-08 2017-01-12 이창우 병목 하단 밀착 구조의 점탄성 연결캡을 포함하는 니들 디스크 롤러 장치
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
JP2021517572A (ja) * 2018-03-13 2021-07-26 エルテーエス ローマン テラピー−ジステーメ アーゲー シリコーンアクリルハイブリッドポリマーを含む経皮治療システム
US20210000755A1 (en) * 2018-03-13 2021-01-07 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer
WO2019175106A1 (en) * 2018-03-13 2019-09-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
EP3764996A1 (en) * 2018-03-13 2021-01-20 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
WO2021005117A1 (en) * 2019-07-09 2021-01-14 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising an active agent-containing layer comprising a silicone-containing polymer and a skin contact layer comprising a silicone gel adhesive
CN113952319A (zh) * 2021-11-30 2022-01-21 烟台大学 一种含丁丙诺啡的骨架型透皮贴剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU2003297073A1 (en) * 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
CN1943576A (zh) * 2006-10-27 2007-04-11 哈尔滨健迪医药技术有限公司 丁丙诺啡和/或盐酸丁丙诺啡贴剂基质及其贴剂的制备方法
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
CN101612141B (zh) * 2009-07-29 2012-10-03 考司美德制药株式会社 丁丙诺啡贴剂

Also Published As

Publication number Publication date
EP2931263A1 (en) 2015-10-21
CL2015001577A1 (es) 2015-10-02
AR093940A1 (es) 2015-07-01
CN105007906A (zh) 2015-10-28
PH12015501169A1 (en) 2015-08-10
HK1215677A1 (zh) 2016-09-09
PE20151147A1 (es) 2015-08-06
US20180193333A1 (en) 2018-07-12
MX2015007348A (es) 2016-01-20
JP2016502989A (ja) 2016-02-01
ZA201504964B (en) 2017-11-29
US20150306093A1 (en) 2015-10-29
SG11201504286VA (en) 2015-06-29
BR112015013660A2 (pt) 2017-07-11
EA201591124A1 (ru) 2015-11-30
IL239223A0 (en) 2015-07-30
AU2013205080A1 (en) 2014-06-26
GB2523715A (en) 2015-09-02
TN2015000201A1 (en) 2016-10-03
GB201512243D0 (en) 2015-08-19
AU2013205080B2 (en) 2016-07-07
AP2015008525A0 (en) 2015-06-30
WO2014090921A1 (en) 2014-06-19
CA2894960A1 (en) 2014-06-19
US20200253957A1 (en) 2020-08-13
DE112013005945T5 (de) 2015-08-27
KR20150096460A (ko) 2015-08-24
TW201438765A (zh) 2014-10-16
NZ628092A (en) 2017-01-27

Similar Documents

Publication Publication Date Title
CR20150360A (es) Sistema de liberación transdérmica
CR20150647A (es) Sistema de liberación transdérmica
CR20140321A (es) Sistema de administracion transdermica que contiene buprenofina
MX2019007391A (es) Sistema terapeutico transdermico que contiene asenapina.
MY188139A (en) Sodium channel modulators for the treatment of pain
ECSP12011834A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos.
MX2019007389A (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno.
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
EP3141603A4 (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
BR112016000350A8 (pt) métodos de tratamento de lesões inflamatórias da rosácea e usos de uma composição farmacêutica
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
CL2016000313A1 (es) Compuestos de benzoxaborol tricíclicos y usos de los mismos
MX377089B (es) Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral.
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
AR093118A1 (es) Composiciones y metodos para la administracion transdermica de anfetamina
MX2014011855A (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
EA201400628A1 (ru) Трансдермальная терапевтическая система для введения фентанила или его аналога
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
PY1330684A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
EA201591450A1 (ru) Фармацевтический состав, содержащий гликозаминогликан
MX2014010989A (es) Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos.
MX2015010967A (es) Formulaciones transdermicas de laquinimod.
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
ECSP16069947A (es) Formulaciones tópicas de heparina